This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
HCPLive
DECEMBER 23, 2024
Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.
111 
Frontiers in Cardiovascular Medicine
DECEMBER 20, 2023
Objectives To determine the clinical profile, according to the history of hypertension, the risk of developing hypertension, current antihypertensive treatment and BP control rates in patients with hypertension from the IBERICAN cohort. This analysis shows the baseline clinical characteristics of patients with hypertension.
134 
CardiacWire
FEBRUARY 11, 2024
The associations between obesity and hypertension are widely known, but a new JACC study reveals that weight-reducing gastric bypass surgery has a significant and lasting impact on patients’ need for antihypertensives. vs. 2.4%) All gastric bypass patients eliminated their resistant hypertension (from 15.2%
111 
HCPLive
FEBRUARY 2, 2024
Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.
105 
CardiacWire
DECEMBER 6, 2024
All patients were either obese or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, or CVD. Over SURMOUNT-5s 72 week duration , 751 participants across the U.S. Tirzepatide led to an average weight loss of 20.2%, well above semaglutides 13.7%. vs. 16.1%).
90 
American College of Cardiology
MARCH 6, 2024
Bariatric surgery is effective in controlling hypertension (HTN) and polypharmacy in patients with obesity, according to results from the GATEWAY clinical trial published Feb. 5 in JACC.
69 
American College of Cardiology
AUGUST 7, 2024
In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.
61 
Cardiometabolic Health Congress
JANUARY 3, 2024
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
97 
Medical Xpress - Cardiology
OCTOBER 15, 2024
Obesity is a widespread public health challenge in the Middle East, maintaining prevalence in 54.2% Overweight and obese women have a higher risk of hypertension and cardiovascular risk factors than women with a standard BMI, according to an analysis of the ANCORS-YW STUDY presented at ACC Middle East 2024. of women and 31.4%
52 
Heart BMJ
SEPTEMBER 25, 2024
Background The relationships between various obesity measures and hypertensive disorders of pregnancy (HDP) remain inadequately explored, and their causal links are not well understood. to 2.15; obesity: OR=3.77, 95% CI 3.45 to 1.90; obesity: OR=3.46, 95% CI 3.16 to 2.15; obesity: OR=3.77, 95% CI 3.45
52 
American College of Cardiology
JANUARY 8, 2024
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
71 
Science Daily - Heart Disease
MARCH 7, 2024
Adults who had amblyopia ('lazy eye') in childhood are more likely to experience hypertension, obesity, and metabolic syndrome in adulthood, as well as an increased risk of heart attack, finds a new study.
123 
CardiacWire
AUGUST 23, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression. mm Hg systolic and 4.2 of placebo-takers.
64 
Cardiovascular Diabetology
JANUARY 7, 2025
Among hypertensive cohorts across different nations, the relationship between the triglyceride-glucose index (TyG) and its conjunction with obesity metrics in relation to cardiovascular disease (CVD) incidence.
52 
HCPLive
OCTOBER 30, 2024
A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.
59 
MIBHS
FEBRUARY 15, 2025
High blood pressure, also known as hypertension, is a common condition that affects millions of people worldwide. Often referred to as the silent killer, hypertension can quietly damage your heart and other vital organs over time. Hypertension is diagnosed when blood pressure consistently reads 130/80 mm Hg or higher.
Circulation
NOVEMBER 11, 2024
Introduction:Obesity is rising in prevalence worldwide and co-exists in patients with group 1 pulmonary hypertension (PH). Clinical and hemodynamic implications of having obesity in group 1 PH remain unknown.Hypothesis. There was no difference in survival among patients with and without obesity (HR 1.15; 95% CI 0.95-1.38;
40 
Science Daily - Heart Disease
FEBRUARY 5, 2024
Bariatric surgery is more effective in controlling hypertension rates, or high blood pressure, in people with obesity and uncontrolled high blood pressure compared to blood pressure medication alone, according to a new study.
113 
CardiacWire
MAY 8, 2024
Officially published by the AHA six months ago, CKM syndrome defines the connections and risks associated with obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. Stage 2 (metabolic risk factors like hypertension, diabetes, CKD) – 49% Stage 3 (kidney disease or high cardiovascular risks) – 5.4%
116 
Hypertension Journal
NOVEMBER 8, 2023
Hypertension, Ahead of Print. Alterations in microcirculation play a crucial role in the pathogenesis of cardiovascular and metabolic disorders such as obesity and hypertension. In obesity, PVAT becomes enlarged and inflamed, and the bioavailability of adiponectin is reduced.
40 
Cardiovascular Diabetology
JANUARY 23, 2025
Obesity, a major risk factor for cardiovascular disease (CVD), is associated with hypertension and vascular dysfunction. Perivascular adipose tissue (PVAT), a metabolically active tissue surrounding blood vess.
52 
Open Heart
MAY 23, 2024
Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. Hypertension and diabetes were independent risk factors for pre-eclampsia. It is not known whether heart failure increases the risk of pre-eclampsia.
Stroke Journal
FEBRUARY 1, 2024
Hypertension and obesity were defined using AHA and CDC guidelines. We used logistic regression to estimate the odds of hypertension and obesity among family types adjusted for age and gender and assessed nativity modification using an interaction term.Results:Among 147 Hispanic adults, 56.0% had hypertension, 58.2%
40 
Journal of the American Heart Association
DECEMBER 29, 2023
Multivariable logistic models evaluated associations of RARs with prevalent CVD, hypertension, obesity, and central adiposity. A more active wake period was associated with 19% to 72% lower CVD, hypertension, obesity, and central adiposity odds.
40 
Journal of the American Heart Association
DECEMBER 29, 2023
Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration.
45 
Hypertension Journal
DECEMBER 11, 2023
Hypertension, Ahead of Print. Demographic characteristics and trajectories were compared by hypertensive status (systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or use of antihypertensive medications) at 1 year. Pregnancy BPs were obtained during prenatal visits; postpartum BPs were prospectively obtained through home monitoring.
DAIC
JUNE 18, 2024
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8
105 
Hypertension Journal
NOVEMBER 29, 2023
Hypertension, Ahead of Print.
40 
Cardiometabolic Health Congress
NOVEMBER 25, 2024
Don’t worry—you can still access the 19th Annual CMHC sessions through our On-Demand platform, which offers 14 CME credits across four comprehensive tracks: Cardiorenal Health: Stay up-to-date with the latest on therapies for resistant hypertension, chronic kidney disease markers, and cardiac risk assessment tools.
52 Journal of the American Heart Association
DECEMBER 29, 2023
The goal of this study was to investigate the contribution of the renin–angiotensin–aldosterone system to the mechanism by which MSEW increases blood pressure and vasomotor sympathetic tone in obese male mice.Methods and ResultsMice were exposed to MSEW during postnatal life. Undisturbed litters served as controls.
40 
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%
Circulation
JUNE 4, 2024
We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% to 26.8%) and obesity (43.1% in 2020 to 61.0% Diabetes (16.3% Prevalences of coronary disease (7.8%
81 
Cardiovascular Diabetology
JANUARY 27, 2024
This study used a bidirectional 2-sample Mendelian randomization study to investigate the potential causal links between mtDNA copy number and cardiometabolic disease (obesity, hypertension, hyperlipidaemia, t.
59 
Cardiometabolic Health Congress
JULY 25, 2024
Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C.
100 
Medical Xpress - Cardiology
MARCH 25, 2025
The findings are particularly significant as the prevalence of major cardiometabolic risk factors such as hypertension, diabetes, and obesity continues to rise despite advancements in health care and treatment. This trend highlights the need for better early detection and intervention.
52 
HCPLive
FEBRUARY 19, 2025
This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.
52 
Frontiers in Cardiovascular Medicine
JULY 17, 2024
Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heart failure (HF), and hypertension] prognosis and mortality. Finally, we summarized the mechanism of the “obesity paradox.”
Circulation
NOVEMBER 11, 2024
Empagliflozin (EMPA), the clinical benchmark, was used to confirm the relevance of the model.Methods:To induce obesity/metabolic syndrome, mild and HFpEF, C57BL6N mice were fed HFD (60% Kcal from fat) and water with L-NAME (0.5g/l) We evaluated the presence of HFpEF hallmark and corroborated our data with literature. l) for 8 weeks.
American College of Cardiology
NOVEMBER 5, 2024
The idea that obesity increases the risk of heart failure seems like an obvious conclusion. After all, as the Framingham Heart Study clearly showed, obesity and overweight are significantly associated with a higher risk of hypertension, angina and coronary heart disease.
Stroke Journal
FEBRUARY 1, 2024
Introduction:The paucity of large-scale data exploring the effect of prior bariatric surgery on recurrent stroke outcomes in elderly obese stroke survivors led us to address the gap, with an emphasis on the risk of recurrent stroke and its trends.Methods:A retrospective study was conducted using National Inpatient Sample data from 2016-2019.
40 
Cardiovascular Diabetology
FEBRUARY 9, 2024
Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once week.
52 
Journal of Clinical Investigation - Cardiology
DECEMBER 15, 2023
Using a 2-hit preclinical model of cardiometabolic HFpEF that induces obesity and hypertension, we found that cardiac T cell infiltration and lymphoid expansion occurred concomitantly with cardiac pathology and that diastolic dysfunction, cardiomyocyte hypertrophy, and cardiac phospholamban phosphorylation were T cell dependent.
Circulation
NOVEMBER 11, 2024
Hypertension can often be seen in settings of obesity, leptin resistance, and insulin resistance, though the exact mechanistic interaction of these conditions has yet to be elucidated. Inhibition of the mammalian target of rapamycin (mTOR), a major regulator of both insulin and leptin pathways, promotes symptoms of metabolic syndrome.
40 
Journal of the American Heart Association
FEBRUARY 14, 2024
Driven by common pathophysiologic underpinnings (eg, inflammation and neurohormonal dysregulation), cardiovascular disease, cognitive impairment, and frailty also share the following risk factors: hypertension, diabetes, obesity, sedentary behavior, and tobacco use.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content